Navigation Links
Three Leading Proxy Advisory Firms are Unanimous in Recommending LCA-Vision Stockholders Support the Current Board of Directors
Date:3/11/2009

PROXY Governance Joins RiskMetrics and Glass Lewis in Urging Stockholders to Vote the GOLD Card

CINCINNATI, March 11 /PRNewswire-FirstCall/ -- LCA-Vision Inc. (Nasdaq: LCAV) announces that the independent proxy advisory firm PROXY Governance, Inc. has joined RiskMetrics Group's ISS Governance Services and Glass Lewis & Co., LLC in recommending that LCA-Vision stockholders vote to retain the Company's current management and Board of Directors and reject all proposals made by the Joffe Group's consent solicitation.

The PROXY Governance report includes an analysis of proposals and supporting statements made by the dissident group and the views of LCA-Vision's Board and management. The report, issued March 6, recommends that LCA-Vision stockholders vote in support of the Board and management on all proposals, stating, "We believe shareholders would be better served by allowing the current board and its management team to continue executing on their strategic plan."

"We are delighted all three of the advisory firms that reviewed the situation have unanimously recommended that LCA-Vision stockholders support our current executive team and Board of Directors. Each of these firms has conducted an independent and proprietary analysis of the situation, and each has come to the same conclusion: LCA-Vision stockholders should vote the GOLD card," said Steven Straus, LCA-Vision chief executive officer.

"The latest report, from PROXY Governance, gives our management team and Board high marks for our aggressive response to the precipitous decline in consumer discretionary spending that has impacted our business, as well as others in our industry, by implementing numerous initiatives that position LCA-Vision and our LasikPlus(R) Vision Centers for growth and a prosperous future, while prudently managing our appreciable cash," he said.

In its report, PROXY Governance states, among other things:

  • LCA-Vision has "not only laid out a longer-term strategy to transition from a one-off-transaction business model to an ongoing lifetime care model - allowing it to both tap more reliable revenue streams and build a broader, stronger brand - but has also identified numerous near-term tactical improvements in its operations, quality, and marketing."
  • LCA-Vision's market share improvement is "most compelling against the backdrop of a continuing macroeconomic decline - and particularly the ongoing decline in consumer confidence, to which the business had been so highly correlated." According to independent researcher Market Scope(R), LLC, LCA-Vision's share of the laser vision correction services market increased to 11.9% in the fourth quarter of 2008 from 10.5% in the third quarter of 2008.
  • The dissidents' strategy that optimizing certain business practices could drive a higher prospect-to-patient yield, "while heavy on criticisms of the company's declining performance - is particularly light on details or what, exactly, is suboptimal about those processes now, and how, specifically, they would improve the yield."
  • The dissidents' "contention that marketing costs can be 'fixed' - roughly halved to the $250 per procedure the company spent several years ago - without any corresponding falloff in procedure volume seems questionable." In further evaluating marketing costs, PROXY Governance finds that more useful measures "would include a controlled study of marketing campaign in test markets - such as the company conducted in Q4 2008, when it demonstrated its revised marketing strategy could directly drive a 34% increase in procedures."
  • The dissident group's "prescription for righting the company," "seems only to point back to many of the strategic and tactical improvements the company has made since removing S. Joffe from office."

Due to the nature of the Consent process, your voting instruction is extremely important and time sensitive. LCA-Vision urges all stockholders to vote their GOLD cards to REVOKE CONSENT on all three proposals. Please discard any proxy card that you receive from the Joffe Group. If you have already voted to consent and wish to change your vote, you have every right to revoke your consent and vote the GOLD proxy. Only the latest dated card counts.

LCA-Vision filed its Definitive Consent Revocation Statement ("Consent Revocation Statement") with the Securities and Exchange Commission on Monday, February 9, 2009, and copies of the Consent Revocation Statement with a GOLD Consent Revocation Card were mailed to stockholders beginning February 10, 2009. The Consent Revocation Statement can be obtained immediately from the SEC's website at the following link:

http://idea.sec.gov/Archives/edgar/data/1003130/000114420409006021/v139094_defc14a.htm

or from the Investor Relations section of the Company's website at www.lasikplus.com and www.lca-vision.com. Copies of the Consent Revocation Statement and consent revocation card may also be obtained from Georgeson Inc.

Additional Information:

Georgeson Inc. has been retained by LCA-Vision as consent revocation solicitation agent. Stockholders with questions are encouraged to call Georgeson toll-free 1-800-457-0109. Copies of the Company's Consent Revocation Statement, and any other documents filed by LCA-Vision with the SEC in connection with the consent solicitation can be obtained free of charge from the SEC's website at www.sec.gov, from the Company's website at www.lasikplus.com and www.lca-vision.com, or from Georgeson.

About LCA-Vision Inc./LasikPlus(R)

LCA-Vision Inc., a leading provider of laser vision correction services under the LasikPlus(R) brand, operates 75 LasikPlus(R) fixed-site laser vision correction centers in 32 states and 57 markets in the United States and a joint venture in Canada. Additional company information is available at www.lca-vision.com and www.lasikplus.com.

      Earning Trust Every Moment. 
                                         Transforming Lives Every Day.
    For Additional Information

    Company Contact:                   Investor Relations Contact:
    Barb Kise                          Jody Cain
    LCA-Vision Inc.                    Lippert/Heilshorn & Associates
    513-792-9292                       310-691-7100


'/>"/>
SOURCE LCA-Vision Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Living With Grief: Diversity and End-of-Life Care' National Teleconference Offered at Three Bay Area Locations
2. Promising Three-year Data: Saving Limbs With Drug-Eluting Stents
3. Three Cetaphil(R) Products Awarded National Eczema Association Seal of Acceptance
4. United States Joins Suit Against Community Health Systems Inc. and Three of Its Hospitals in New Mexico
5. Three Healthcare GPOs to Offer Masimo Rainbow SET(R) Pulse CO-Oximetry(TM) to Their Members
6. Glass Lewis Recommends Shareholders Support LCA-Vision Board of Directors and Reject All Three Proposals by Dissident Joffe Group
7. Clinipace Recently Awarded $2.8 Million to Manage Three New Clinical Projects
8. 6th Annual World Health Care Congress to Convene Preeminent Leaders for Three Days on Rebuilding Health Care
9. One in Three Cancer Survivors on Unemployment Line
10. Three Miami Physicians and Three Medical Workers Charged With $10 Million Medicare Fraud Scheme
11. Inviro Medical Devices Is Awarded a Three Year Contract with Leading GPO Novation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... , ... December 04, 2016 , ... ... major cosmetic surgery can now take advantage of a cosmetic procedure known as ... rejuvenation treatment that reduces the appearance of age spots, fine lines, uneven ...
(Date:12/4/2016)... ... December 04, 2016 , ... Responsible dental care hinges ... brush properly to achieve optimal results. This important necessity inspired an inventor from Las ... a way to ensure that people break or avoid bad techniques of brushing the ...
(Date:12/2/2016)... ... ... Lori G. Cohen and Sara K. Thompson , shareholders in global ... Institute’s 21st Drug & Medical Device Litigation Conference , taking place in New York ... who chairs the firm’s Pharmaceutical, Medical Device & Health Care Litigation Practice and the ...
(Date:12/2/2016)... ... December 02, 2016 , ... On Dec. 2, 2016, CURE® magazine will host ... honoring the 2016 MPN Heroes—eight individuals who have made a difference in the field ... the standard of care, demonstrating leadership within the MPN community and/or a commitment to ...
(Date:12/2/2016)... Dothan, AL (PRWEB) , ... December 02, 2016 ... ... leaders from across the Dothan-Wiregrass Area in Alabama are expected to attend the ... Mike Schmitz, will help provide scholarship funds for area students and operating support ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... , Dec. 5, 2016 ... hydroxyurea (HU) in Complete Hematologic Response (CHR) ... ropeginterferon alfa-2b versus HU AOP will submit ... CONTINUATION-PV to obtain European marketing authorization in the coming months ... the FDA as it seeks approval for commercialization in the ...
(Date:12/4/2016)... 2016 Sickle cell disease (SCD) is an ... cells that get stuck in veins and block blood ... and complications leading to death. Each year, approximately 300,000 ... most of them lack access to comprehensive care or ... therapy for SCD, a pill called hydroxyurea approved more ...
(Date:12/2/2016)... SILVER SPRING, Md. , Dec. 2, 2016 /PRNewswire-USNewswire/ ... a new indication for Jardiance (empagliflozin) to reduce the ... 2 diabetes mellitus and cardiovascular disease. ... adults with type 2 diabetes mellitus," said Jean-Marc ... Metabolism and Endocrinology Products in FDA,s Center for Drug ...
Breaking Medicine Technology: